Trials / Completed
CompletedNCT04768842
A Study of Two Different Formulations of LY3209590 in Healthy Participants
Comparative Pharmacokinetics of LY3209590 After Administration of a Lyophilized Formulation and a Solution Formulation in Healthy Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 50 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The main purpose of this study is to look at the amount of the study drug, LY3209590, that gets into the blood stream and how long it takes the body to get rid of LY3209590 when given as different formulations. The tolerability of LY3209590 will also be evaluated and information about any side effects experienced will be collected. The study will last up to 142 days.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3209590 | Administered SC. |
Timeline
- Start date
- 2021-03-03
- Primary completion
- 2021-09-03
- Completion
- 2021-09-03
- First posted
- 2021-02-24
- Last updated
- 2021-09-27
Locations
1 site across 1 country: United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04768842. Inclusion in this directory is not an endorsement.